Drugs / Polyethylene Glycol Somatropin (rDNA origin)
Polyethylene Glycol Somatropin (rDNA origin)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06448195 | Jan 2023 → Dec 2024 | — | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene Glycol Somatropin (rDNA origin) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06448195 ↗ |
| Action | Restore | “growth hormone replacement therapy” NCT06448195 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human growth hormone” NCT06448195 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT06448195 ↗ |